Last reviewed · How we verify
A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers
The objective of this study is to evaluate the safety, tolerance, pharmacokinetics and the potential immunological reaction of single intravenous recombinant human thymosin β4（NL005）or placebo 0.5, 2.0,5.0μg/kg in Chinese healthy volunteers.30 volunteers will be randomly assigned to one of three groups to receive either NL005 or placebo for 10 consecutive days.
Details
| Lead sponsor | Beijing Northland Biotech. Co., Ltd. |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 30 |
| Start date | Mon Jul 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Jul 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Healthy
Interventions
- Recombinant Human Thymosin β4
- Placebo
Countries
China